Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report

被引:3
|
作者
Kawazoe, Tetsuro [1 ]
Ito, Shuhei [1 ]
Ohgaki, Kippei [1 ]
Fujinaka, Yoshihiko [1 ]
Funakoshi, Hiroki [1 ]
Otake, Akihiko [1 ]
Wang, Huanlin [1 ]
Morita, Kazutoyo [1 ]
Fushimi, Fumiyoshi [2 ]
Ikeda, Yoichi [1 ]
机构
[1] Kyushu Cent Hosp Mutual Aid Assoc Publ Sch Teacher, Dept Gastrointestinal Surg, 3 23 1 Shiobaru,Minami Ku, Fukuoka, Fukuoka 8158588, Japan
[2] Kyushu Cent Hosp Mutual Aid Assoc Publ Sch Teacher, Dept Pathol, Fukuoka, Japan
关键词
Esophageal squamous cell carcinoma; Conversion surgery; Immunotherapy; Older patients; GASTRIC-CANCER; PLUS; 5-FLUOROURACIL; ELDERLY-PATIENTS; PHASE-II; THERAPY; CHEMORADIOTHERAPY; IMMUNOTHERAPY; CISPLATIN;
D O I
10.1186/s40792-023-01634-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundChemotherapy and chemoradiotherapy are common treatments for esophageal squamous cell carcinoma with distant metastasis; however, the prognosis remains poor, and complete remission is difficult to achieve. Here, we report a case of an older adult patient with esophageal squamous cell carcinoma who underwent surgery following combined treatment of immunotherapy and chemotherapy and achieved pathological complete response.Case presentationAn 80-year-old woman presenting with difficulty swallowing was referred to our hospital. She was diagnosed with esophageal squamous cell carcinoma with distant metastasis of the lymph node at the dorsal side of the IVC and the left supraclavicular lymph node. She was treated with pembrolizumab, cisplatin, and 5-fluorouracil. After four pharmacotherapy courses, primary tumor and metastatic lymph node shrinkage was observed. The patient underwent thoracoscopic subtotal esophagectomy and regional lymph node dissection. The lymph node at the dorsal side of the IVC was not resected, and the left supraclavicular lymph node was removed. Histological examination revealed complete response with no residual tumor or lymph node metastasis. The patient had no recurrence 10 months postoperatively without adjuvant chemotherapy.ConclusionsConversion surgery following preoperative therapy, including immunotherapy, may be an effective treatment strategy for improving survival in patients with esophageal squamous cell carcinoma even among older adult patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma
    Matsuda, S.
    Tsubosa, Y.
    Sato, H.
    Takebayashi, K.
    Kawamorita, K.
    Mori, K.
    Niihara, M.
    Tsushima, T.
    Yokota, T.
    Onozawa, Y.
    Yasui, H.
    Takeuchi, H.
    Kitagawa, Y.
    DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [42] Stage II squamous cell carcinoma of the vagina in a patient with bloom syndrome: A case report
    Goudge, Christine S.
    Downs, Levi S.
    Judson, Patricia L.
    Argenta, Peter A.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2007, 52 (06) : 557 - 559
  • [43] Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report
    Hirose, Kosuke
    Saeki, Hiroshi
    Nakashima, Yuichiro
    Kamori, Tomohiro
    Fujimoto, Yoshiaki
    Kawazoe, Tetsuro
    Matsuoka, Hiroya
    Haruta, Yasuhiro
    Sasaki, Shun
    Jogo, Tomoko
    Hu, Qingjiang
    Tsuda, Yasuo
    Ando, Koji
    Oki, Eiji
    Hiratsuka, Ryuzo
    Oda, Yoshinao
    Mori, Masaki
    SURGICAL CASE REPORTS, 2019, 5 (1)
  • [44] Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report
    Kosuke Hirose
    Hiroshi Saeki
    Yuichiro Nakashima
    Tomohiro Kamori
    Yoshiaki Fujimoto
    Tetsuro Kawazoe
    Hiroya Matsuoka
    Yasuhiro Haruta
    Shun Sasaki
    Tomoko Jogo
    Qingjiang Hu
    Yasuo Tsuda
    Koji Ando
    Eiji Oki
    Ryuzo Hiratsuka
    Yoshinao Oda
    Masaki Mori
    Surgical Case Reports, 5
  • [45] Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case
    Imai S.
    Suzuki A.
    Yamamoto Y.
    Koyama M.
    Sugiyama S.
    Kitazawa M.
    Miyagawa Y.
    Miyagawa S.
    Clinical Journal of Gastroenterology, 2017, 10 (4) : 336 - 341
  • [46] Combined immune checkpoint inhibitor and chemotherapy is effective in a patient with ALK rearranged non-small cell lung cancer: a case report
    Xia, Lexin
    Hu, Hanguang
    Li, Wen
    Shen, Huahao
    Xia, Yang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (03) : 2045 - 2048
  • [47] Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor
    Kawai, Hideki
    Saito, Yoshitaro
    Demura, Ryo
    Odaka, Hidesato
    Takahashi, Susumu
    Takahashi, Kento
    Kurokawa, Hirokazu
    Enomoto, Katsuhiko
    THORACIC CANCER, 2018, 9 (04) : 495 - 497
  • [48] Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer with peritoneal metastasis.
    Liang, Huayuan
    Li, Fengping
    Zhang, Huimin
    Xie, Qing
    Zhong, Rou
    Huang, Kaihua
    Yan, Xiao
    Li, Zhiwei
    Huang, Zhicheng
    Hu, Yanfeng
    Yu, Jiang
    Liu, Hao
    Li, Guoxin
    Zhao, Liying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 281 - 281
  • [49] Case report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma
    Wu, Shilong
    Xu, Chenyang
    Liu, Huafeng
    FRONTIERS IN MEDICINE, 2024, 11
  • [50] Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.
    Huang, Shujie
    Wu, Hansheng
    Cheng, Chao
    Zhou, Ming
    Xu, Enwu
    Lin, Wanli
    Wang, Guangsuo
    Tang, Jiming
    Ben, Xiaosong
    Zhang, Dongkun
    Xie, Liang
    Zhou, Haiyu
    Chen, Gang
    Zhuang, Weitao
    Tang, Yong
    Xu, Fangping
    Fu, Junhui
    Qiao, Guibin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16045 - E16045